EUCTR2013-005508-33-AT进行中（未招募）1 期
Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients with non-malignant diseases - Treosulfan-based versus Busulfan-based conditioning in paediatric patients with non-malignant diseas
medac Gesellschaft fuer klinische Spezialpräparate mbH0 个研究点目标入组 100 人开始时间: 2014年7月8日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Non-malignant disease indicated for first myeloablative allogeneic HSCT, including inborn errors of metabolism, primary immunodeficiencies, haemoglobinopathies and bone marrow failure syndromes.
- •2. First allogeneic HSCT.
- •3. Available matched sibling donor (MSD), matched family donor (MFD) or matched unrelated donor (MUD). For bone marrow (BM) and peripheral blood (PB) match is defined as at least 9/10 allele matches after four digit typing in human leucocyte antigen (HLA)-A, -B, -C, –DRB1 and DQB1 antigens. For umbilical cord blood (UCB) match is defined as at least 5/6 matches after two digit typing in HLA-A and -B and four digit typing in DRB1 antigens.
- •4. Age at time of registration from 28 days to less than 18 years of age.
- •5. Lansky (patients <16 years of age) or Karnofsky (patients = 16 years of age) performance score of at least 70%.
- •6. Written informed consent of the parents/legal guardians and patient’s assent/consent according to national regulations.
- •7. Female patients of child-bearing potential or partner of male patients with child-bearing potential must use a highly effective method of contraception (pearl index < 1%) such as complete sexual abstinence, combined oral contraceptive, hormone intrauterine contraceptive device (IUCD), vaginal hormone ring, transdermal contraceptive patch, contraceptive implant or depot contraceptive injection in combination with a second method of contraception like a condom or a cervical cap / diaphragm with spermicide or surgical sterilisation (vasectomy) in male patients or male partners during the study and at least six months thereafter.
- •8. Negative pregnancy test for females of child-bearing potential.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 100
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Second or later HSCT.
- •2. HSCT from mismatched donor (less than 9/10 BM/peripheral blood stem cells (PBSC) or less than 5/6 matched cord donor).
- •3. Preterm newborn infants (<37 weeks gestational age) and term newborn infants aged 0 – 27 days at time of registration.
- •4. Obese paediatric patients with body mass index weight (kg)/[height (m)]² > 30 kg/m².
- •5. Diagnosis of Fanconi anaemia and other chromosomal breakage disorders, radiosensitivity disorders (deoxyribonucleic acid (DNA) Ligase 4, Cernunnos- X-ray repair cross-complementing protein 4 (XRCC4) like factor (XLF), Nijmegen Breakage Syndrome (NBS)) and Dyskeratosis Congenita.
- •6. Treatment with cytotoxic drugs within 10 days prior to day 7.
- •7. Impaired liver function indicated by Bilirubin > three times the upper limit of normal (ULN) or aspartate aminotransferase/alanine aminotransferase (AST/GOT, ALT/GPT) > ten times ULN, or clinically significant coagulopathy, or active infectious hepatitis with clinical evidence.
- •8. Impaired renal function indicated by estimated glomerular filtration rate ([GFR], according to the Schwartz formula) < 60 mL/min/1.73m2.
- •9. Impaired cardiac function: severe cardiac insufficiency indicated by left ventricular ejection fraction (LVEF) ? 35%.
- •10. Requirement for supplementary continuous oxygen.
- •11. Severe active infection requiring deferral of conditioning.
- •12. Human immunodeficiency virus (HIV) positivity.
- •13. Severe concomitant illness, comorbidity or condition that would severely limit life expectancy.
- •14. Known pregnancy, breast feeding.
- •15. Known hypersensitivity to Treosulfan, Busulfan, Fludarabine and/or Thiotepa.
- •16. Participation in another interventional clinical study with an experimental drug, within four weeks prior to patient inclusion.
研究者
相似试验
进行中（未招募）
1 期
Comparison of Treosulfan-based with Busulfan-based conditioning in paediatric patients with non-malignant diseasesEUCTR2013-005508-33-PLmedac GmbH100
进行中（未招募）
不适用
Comparison of Treosulfan-based with Busulfan-based conditioning in paediatric patients with non-malignant diseasesMale and female children with non-malignant diseases requiring myeloablative conditioning treatment with following allogeneic haematopoietic stem cell transplantation (allo-HSCT) – i.e. primary immunodeficiencies, inborn errors of metabolism, haemoglobinopathies and bone marrow failure syndromes.MedDRA version: 18.0Level: HLTClassification code 10021606Term: Inborn errors of metabolism NECSystem Organ Class: 100000004850MedDRA version: 18.0Level: HLTClassification code 10036700Term: Primary immunodeficiency syndromesSystem Organ Class: 100000004870MedDRA version: 18.0Level: HLTClassification code 10018903Term: Haemoglobinopathies congenitalSystem Organ Class: 100000004850EUCTR2013-005508-33-ITmedac GmbH100
进行中（未招募）
1 期
Comparison of Treosulfan-based with Busulfan-based conditioning in paediatric patients with non-malignant diseasesMale and female children with non-malignant diseases requiring myeloablative conditioning treatment with following allogeneic haematopoietic stem cell transplantation (allo-HSCT) – i.e. primary immunodeficiencies, inborn errors of metabolism, haemoglobinopathies and bone marrow failure syndromes.MedDRA version: 20.0Level: HLTClassification code 10021606Term: Inborn errors of metabolism NECSystem Organ Class: 100000004850MedDRA version: 20.0Level: HLTClassification code 10036700Term: Primary immunodeficiency syndromesSystem Organ Class: 100000004870MedDRA version: 20.0Level: HLTClassification code 10018903Term: Haemoglobinopathies congenitalSystem Organ Class: 100000004850EUCTR2013-005508-33-DEmedac Gesellschaft für klinische Spezialpräparate mbH100
进行中（未招募）
1 期
Comparison of Treosulfan-based with Busulfan-based conditioning in paediatric patients with non-malignant diseasesMale and female children with non-malignant diseases requiring myeloablative conditioning treatment with following allogeneic haematopoietic stem cell transplantation (allo-HSCT) – i.e. primary immunodeficiencies, inborn errors of metabolism, haemoglobinopathies and bone marrow failure syndromes.MedDRA version: 20.0Level: HLTClassification code 10021606Term: Inborn errors of metabolism NECSystem Organ Class: 100000004850MedDRA version: 20.0Level: HLTClassification code 10036700Term: Primary immunodeficiency syndromesSystem Organ Class: 100000004870MedDRA version: 20.0Level: HLTClassification code 10018903Term: Haemoglobinopathies congenitalSystem Organ Class: 100000004850EUCTR2013-005508-33-CZmedac Gesellschaft für klinische Spezialpräparate mbH100
进行中（未招募）
1 期
Conditioning treatment with treosulfan or busulfan for chemotherapy prior to stem cell transplantation in patients with leukemia.EUCTR2008-002356-18-DEmedac Gesellschaft für klinische Spezialpräparate mbH960